Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
| Revenue (TTM) | $7.94M |
| Gross Profit (TTM) | $-8.80M |
| EBITDA | $-20.20M |
| Operating Margin | -3038.00% |
| Return on Equity | -51.30% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.44 |
| Book Value | $2.09 |
| Price-to-Book | 2.30 |
| Price-to-Sales (TTM) | 14.21 |
| EV/Revenue | 7.82 |
| EV/EBITDA | -6.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.60% |
| Shares Outstanding | $23.46M |
| Float | $17.84M |
| % Insiders | 14.69% |
| % Institutions | 35.37% |
Volatility is currently expanding